Goldhaber S Z
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
Chest. 1995 Jan;107(1 Suppl):45S-51S. doi: 10.1378/chest.107.1_supplement.45s.
Lack of familiarity with pulmonary embolism (PE) thrombolysis is understandable because most hospitals treat just a few patients each year with recognized massive PE. Therefore, most physicians are inexperienced in administering PE thrombolysis, even though they utilize these agents routinely for acute myocardial infarction. Current estimates are that no more than 10% of patients with PE receive thrombolysis in the United States. This situation may be changing now, because PE thrombolysis appears to have expanded indications. Contemporary PE thrombolysis can now be given with simpler, less expensive protocols than were previously available. In the past, this treatment strategy had been rightly regarded as a heroic measure that consumed hospital resources and physicians' time. Today, PE thrombolysis can be applied with a 2 week "time window," no mandatory angiography in many cases, a brief infusion through a peripheral vein, and no special laboratory tests.
对肺栓塞（PE）溶栓治疗缺乏了解是可以理解的，因为大多数医院每年仅治疗少数几例确诊为大面积PE的患者。因此，尽管大多数医生在急性心肌梗死的治疗中经常使用这些药物，但他们在进行PE溶栓治疗方面经验不足。目前估计，在美国，接受溶栓治疗的PE患者不超过10%。现在这种情况可能正在改变，因为PE溶栓治疗的适应证似乎有所扩大。与以前相比，当代PE溶栓治疗现在可以采用更简单、成本更低的方案。过去，这种治疗策略被正确地视为一种消耗医院资源和医生时间的大胆措施。如今，PE溶栓治疗可以在2周的“时间窗”内进行，在许多情况下无需进行强制性血管造影，通过外周静脉进行短时间输注，也无需进行特殊实验室检查。
